Last updated: July 27, 2026
Boehringer Ingelheim Pharmaceuticals Inc. sued Cadila Healthcare Limited in the District of Delaware in 2019 under the Hatch-Waxman framework (Paragraph IV posture). The case is docketed as 1:19-cv-01295. The provided prompt does not include the operative complaint, asserted patents, ANDA reference product details, Teva/Mylan-style labeling, or claim construction outcomes. Without those case-specific documents and dates, a complete and accurate litigation summary cannot be produced under the required standards.
What patents did Boehringer assert against Cadila in 1:19-cv-01295?
A litigation analysis that identifies the exact patent numbers, inventors, assignees, asserted claims, and alleged infringement (and whether the asserted patents are Orange Book-listed) requires the complaint and any amended complaint or preliminary injunction briefing for 1:19-cv-01295. The prompt contains no such information.
Which Orange Book patents were allegedly infringed
Mapping Hatch-Waxman litigation to FDA listings requires: (i) the ANDA number and product name, (ii) the FDA Reference Listed Drug, and (iii) the Orange Book patent list tied to the asserted patents. These specifics are not present.
What infringement theory was pled
A defensible infringement summary needs the pleading’s infringement section: method-of-manufacture vs. composition vs. use; plus whether the case centered on bioequivalence, formulation parameters, or dosing regimen. Not provided.
What claims and defenses were at issue in Boehringer v. Cadila 1:19-cv-01295?
A complete litigation summary typically covers asserted claim construction points, invalidity arguments (anticipation/obviousness/indefiniteness/enablement), non-infringement, and statutory defenses. The record is not included in the prompt.
Invalidity and enforceability issues
Patent litigation analysis depends on which grounds were actually raised by Cadila (for example, IPR/anticipation overlap, written description, prosecution history estoppel). Not provided.
Section 271(e)(2) causation and notice
For Paragraph IV cases, the parties often dispute whether the ANDA’s certifications trigger the statutory cause of action and whether notice complied with 21 U.S.C. § 355(j)(2)(B). Not provided.
When did the case move procedurally: TRO, preliminary injunction, Markman, and trial dates?
A timeline requires docket events: complaint filing date, service, responsive pleadings, scheduling order, claim construction hearing dates, summary judgment dates, and any settlement-related entries. The prompt provides none of these.
Has the case reached claim construction or dispositive rulings?
A final or intermediate ruling can materially change patent risk. No rulings are provided.
Was there a settlement or consent judgment?
Settlement affects generic launch risk, including whether any royalty, covenant, or stipulation to final judgment exists. The prompt includes no settlement terms or docket entries.
How did the court handle claim construction for the asserted patents?
Claim construction is often outcome-determinative. A litigation analysis must list:
- the asserted independent and dependent claims
- the court’s constructions
- “plain meaning” disputes
- infringement mapping to constructed elements
None of this is available in the prompt.
What generic entry risks exist for Cadila based on 1:19-cv-01295?
Paragraph IV posture typically translates into:
- an infringement/validity outcome
- a potential 30-month stay (then lifting or expiring based on case status)
- launch-at-risk decisions depending on injunction or summary judgment
To quantify launch risk, the analysis requires the status of any injunctions and the resolution (or dismissal) mechanics. No resolution information is provided.
30-month stay and exclusivity timeline impact
To link to the generic launch date, the analysis needs: ANDA submission date, first FDA approval date of the reference drug, and docket status at 30 months. Not provided.
What is the Orange Book status for the reference listed drug in this dispute?
A correct Orange Book analysis needs the reference listed drug name and the patent list at the time of ANDA filing, including:
- patent expiration dates
- listed formulations (if any)
- patent type (drug substance, drug product, method of use)
The prompt provides no drug identity beyond the parties.
How does Cadila’s position compare with other Hatch-Waxman defendants in the same drug family?
Comparative analysis requires identifying:
- other filed ANDAs
- other Paragraph IV lawsuits by Boehringer
- outcomes (dismissal, summary judgment, settlements)
- any differences in ANDA product composition or labeling
No comparators are provided.
Patent estate strength: how many patents cover the product and how many survive?
This section must be grounded in:
- the complete asserted set
- the total Orange Book listing count at filing
- whether any patents were dismissed or ruled non-infringing/invalid
Without patent numbers and outcomes, the section cannot be completed accurately.
Key takeaways
No litigation-specific assertions, procedural milestones, court rulings, or settlement information are included in the prompt. A complete and accurate litigation summary for Boehringer Ingelheim Pharmaceuticals Inc. v. Cadila Healthcare Limited, 1:19-cv-01295 cannot be produced from the provided information without fabricating case facts.
FAQs
- What is the court and jurisdiction for Boehringer Ingelheim v. Cadila (1:19-cv-01295)?
- Was the case filed under Paragraph IV and what does that imply for generic launch timing?
- Which patents were listed in the Orange Book for the reference drug at the time of Cadila’s ANDA?
- Did the court issue any claim construction or dispositive rulings in 1:19-cv-01295?
- Were there settlement terms affecting final judgment or launch-at-risk dates?
References
- No citable case documents were provided in the prompt (complaint, docket entries, orders, or opinions).
